RU2000131695A - DRUG DELIVERY SYSTEM - Google Patents

DRUG DELIVERY SYSTEM

Info

Publication number
RU2000131695A
RU2000131695A RU2000131695/14A RU2000131695A RU2000131695A RU 2000131695 A RU2000131695 A RU 2000131695A RU 2000131695/14 A RU2000131695/14 A RU 2000131695/14A RU 2000131695 A RU2000131695 A RU 2000131695A RU 2000131695 A RU2000131695 A RU 2000131695A
Authority
RU
Russia
Prior art keywords
delivery system
drug delivery
drug
paragraphs
densely
Prior art date
Application number
RU2000131695/14A
Other languages
Russian (ru)
Other versions
RU2202340C2 (en
Inventor
Вольфганг Флайшер
Карен РАЙМЕР
Ханс Штрайер
Original Assignee
Юроселтик С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юроселтик С.А. filed Critical Юроселтик С.А.
Publication of RU2000131695A publication Critical patent/RU2000131695A/en
Application granted granted Critical
Publication of RU2202340C2 publication Critical patent/RU2202340C2/en

Links

Claims (14)

1. Система доставки лекарственного средства, включающая плотно спрессованное твердое лекарственное средство, характеризующееся практически изотропной структурой в твердом состоянии, содержащее активное вещество, при этом лекарственное средство пригодно для образования вдыхаемых частиц, содержащих указанное активное вещество, а плотно спрессованное твердое лекарственное средство содержит, по меньшей мере, одно активное вещество, которое ассоциировано с липосомами или подобным носителем в виде частиц.1. The drug delivery system, comprising a densely compressed solid drug, characterized by an almost isotropic structure in the solid state, containing the active substance, the drug is suitable for the formation of respirable particles containing the specified active substance, and the densely compressed solid drug contains at least one active substance that is associated with liposomes or a similar particulate carrier. 2. Система доставки лекарства по п. 1, отличающаяся тем, что, по меньшей мере, одно активное вещество, содержащееся в плотно спрессованном лекарственном средстве, инкапсулировано в мембранах указанных липосом и/или ассоциировано с этими мембранами. 2. The drug delivery system according to claim 1, characterized in that at least one active substance contained in the densely compressed drug is encapsulated in the membranes of these liposomes and / or associated with these membranes. 3. Система доставки лекарства по п. 1 и/или 2, отличающаяся тем, что плотно спрессованное твердое лекарственное средство содержит указанные липосомы вместе с вспомогательным веществом, например, носителями. 3. The drug delivery system according to claim 1 and / or 2, characterized in that the densely compressed solid drug contains these liposomes together with an auxiliary substance, for example, carriers. 4. Система доставки лекарства по любому из пп. 1-3, отличающаяся тем, что, по меньшей мере, одно активное вещество, содержащееся в плотно спрессованном твердом лекарственном средстве, выбрано из группы, включающей b2-симпатомиметики с коротким сроком действия, такие как салбутанол, требуталин, фенотерол, бамбутерол, b2-симпатомиметики с большим сроком действия, такие как салметерол, формотерол, кортикостероиды для ингаляции, такие как будезонид, беклометазон, флутиказон, антихолинергические агенты, такие как бромид ипатропия, бромид окситропия, нестероидные антиаллергенные агенты, например, DSCG, недоромил, противовоспалительные агенты, особенно антибиотики и/или антисептики, например, повидониодид, и их комбинации.4. The drug delivery system according to any one of paragraphs. 1-3, characterized in that at least one active substance contained in a densely compressed solid drug is selected from the group consisting of b 2 short-acting sympathomimetics, such as salbutanol, trebutaline, fenoterol, bambuterol, b 2 -simpatomimetiki with long-term action, such as salmeterol, formoterol, corticosteroids for inhalation such as budesonide, beclomethasone, fluticasone, anticholinergic agents such as ipatropium bromide, oxitropium bromide, nonsteroidal anti-allergic agents nap Example, DSCG, Nedoromil, anti-inflammatory agents, especially antibiotics and / or antiseptics, for example, povidoniodide, and combinations thereof. 5. Система доставки лекарства по любому из пп. 1-3, отличающаяся тем, что, по меньшей мере, одно активное вещество, содержащееся в плотно спрессованном твердом лекарственном средстве, выбрано из b-лактамных антибиотиков, таких как пеницилины, цефалоспорины, имипинем; аминогликозидов, таких как тобрамицин, гентамицин; ингибиторов жиразы, таких как офлоксации, ципрофлоксацин, антивирусных агентов, таких как ганцикловир, азидотимидин, антимикотических агентов, таких как полием, азол, вакцин против кори, краснухи, дифтерии, коклюша, полиомиелита и т. п. , вакцин, состоящих практически из вирусных или бактериальных компонентов, вакцин, содержащих ДНК, кодирующую поколение специфических антигенов, опиоидов для облегчения и лечения болевых ощущений, таких как морфин, оксикодон, гидроморфон, бупренорфин, фентанил, алфентанил, сульфентанил и т. п, антиинфекционных агентов, таких как олиго/полирибо- и/или олиго/поли-дезоксирибонуклеиновые кислоты, пептидов, полипептидов, таких как инсулин, низкомолекулярный и высокомолекулярный гепарин, гормонов, таких как факторы роста, гормоны щитовидной железы, половые гормоны, кальцитонин и их композиций. 5. The drug delivery system according to any one of paragraphs. 1-3, characterized in that at least one active substance contained in a densely compressed solid drug is selected from b-lactam antibiotics such as penicillins, cephalosporins, imipineme; aminoglycosides such as tobramycin, gentamicin; fatty inhibitors such as offlocations, ciprofloxacin, antiviral agents such as ganciclovir, azidothymidine, antimycotic agents such as polium, azole, measles, rubella, diphtheria, pertussis, poliomyelitis vaccines, etc., practically viral vaccines or bacterial components, vaccines containing DNA encoding the generation of specific antigens, opioids for the relief and treatment of pain, such as morphine, oxycodone, hydromorphone, buprenorphine, fentanyl, alfentanil, sulfentanil, etc., anti-infectious x agents, such as oligo / polyribo and / or oligo / poly-deoxyribonucleic acids, peptides, polypeptides such as insulin, low molecular weight and high molecular weight heparin, hormones such as growth factors, thyroid hormones, sex hormones, calcitonin and their compositions . 6. Система доставки лекарства по любому из пп. 1-5, отличающаяся тем, что плотно спрессованное твердое лекарственное средство получено путем изостатического прессования под давлением 50-500 МПа. 6. The drug delivery system according to any one of paragraphs. 1-5, characterized in that the densely pressed solid drug is obtained by isostatic pressing under a pressure of 50-500 MPa. 7. Система доставки лекарства по одному из пп. 1-6, отличающаяся тем, что вспомогательное вещество в плотно спрессованном твердом лекарственном средстве выбрано из лактозы, трегалозы, глюкозы, маннита, хлористого натрия и их комбинаций. 7. The drug delivery system according to one of paragraphs. 1-6, characterized in that the excipient in a densely compressed solid drug is selected from lactose, trehalose, glucose, mannitol, sodium chloride, and combinations thereof. 8. Система доставки лекарства по одному из пп. 1-7, отличающаяся тем, что липосомы смешаны с лактозой в отношении, по меньшей мере, 100 вес. ч. лактозы на 1 вес. ч. липосом. 8. The drug delivery system according to one of paragraphs. 1-7, characterized in that the liposomes are mixed with lactose in a ratio of at least 100 weight. including lactose per 1 weight. including liposomes. 9. Система доставки лекарства по одному из пп. 1-5, отличающаяся тем, что плотно спрессованное лекарственное средство подвергнуто обработке подходящими способами для образования частиц, такими как микронизация или истирание. 9. The drug delivery system according to one of paragraphs. 1-5, characterized in that the densely pressed drug is subjected to processing by suitable methods for the formation of particles, such as micronization or abrasion. 10. Система доставки лекарства по п. 9, отличающаяся тем, что образовавшиеся частицы имеют размеры 0,1-50 мкм, предпочтительно 1-8 мкм при введении в легкие и 1-15 мкм при назальном введении. 10. The drug delivery system according to p. 9, characterized in that the formed particles have a size of 0.1-50 microns, preferably 1-8 microns when introduced into the lungs and 1-15 microns when administered nasally. 11. Система доставки лекарства по п. 1, отличающаяся тем, что носитель в виде частиц выбран из микросфер, наночастиц, больших пористых частиц, искусственных оболочек вирусов и подобных фармацевтически приемлемых материалов. 11. The drug delivery system according to claim 1, characterized in that the carrier in the form of particles is selected from microspheres, nanoparticles, large porous particles, artificial envelopes of viruses and similar pharmaceutically acceptable materials. 12. Способ получения плотно спрессованного твердого лекарственного средства по любому из пп. 1-11, отличающийся тем, что липосомы получают или нагружают известным способом, возможно, смешивают с, по меньшей мере, одним вспомогательным веществом и затем формуют изделие путем изостатического прессования. 12. A method of obtaining a tightly compressed solid drug according to any one of paragraphs. 1-11, characterized in that the liposomes are obtained or loaded in a known manner, possibly mixed with at least one auxiliary substance and then the product is molded by isostatic pressing. 13. Способ по п. 12, отличающийся тем, что изостатическое прессование осуществляют при давлениях 50-500 МПа. 13. The method according to p. 12, characterized in that the isostatic pressing is carried out at pressures of 50-500 MPa. 14. Применение плотно спрессованного твердого лекарственного средства в системе доставки лекарства по любому из пп. 1-11 для получения частиц, которые могут быть введены вдуванием и/или ингаляцией при терапевтическом лечении болезней и нарушений работы дыхательных путей, а также болезней и нарушений работы органов в генной терапии или вакцинации. 14. The use of a densely compressed solid drug in the drug delivery system according to any one of paragraphs. 1-11 to obtain particles that can be introduced by insufflation and / or inhalation in the therapeutic treatment of diseases and disorders of the respiratory tract, as well as diseases and disorders of the organs in gene therapy or vaccination.
RU2000131695/14A 1998-05-27 1999-05-27 Drug delivery system RU2202340C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8689598P 1998-05-27 1998-05-27
US60/086,895 1998-05-27

Publications (2)

Publication Number Publication Date
RU2000131695A true RU2000131695A (en) 2002-11-10
RU2202340C2 RU2202340C2 (en) 2003-04-20

Family

ID=22201600

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2000132713/14A RU2212884C2 (en) 1998-05-27 1999-05-27 Preparations used for administration of anti- -inflammatory and especially antiseptic agents and/or agent promoting to wound healing into lower respiratory way
RU2000131695/14A RU2202340C2 (en) 1998-05-27 1999-05-27 Drug delivery system
RU2000132711/14A RU2211693C2 (en) 1998-05-27 1999-05-27 Preparations for injecting antiphlogistic, especially, antiseptic substances and/or those favoring wound healing into superior respiratory pathways and/or ear

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2000132713/14A RU2212884C2 (en) 1998-05-27 1999-05-27 Preparations used for administration of anti- -inflammatory and especially antiseptic agents and/or agent promoting to wound healing into lower respiratory way

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2000132711/14A RU2211693C2 (en) 1998-05-27 1999-05-27 Preparations for injecting antiphlogistic, especially, antiseptic substances and/or those favoring wound healing into superior respiratory pathways and/or ear

Country Status (19)

Country Link
US (2) US20080038330A1 (en)
EP (3) EP1079807B1 (en)
JP (3) JP4741727B2 (en)
KR (3) KR20010043820A (en)
CN (3) CN1303271A (en)
AT (3) ATE319427T1 (en)
AU (3) AU759264B2 (en)
BR (3) BR9911071A (en)
CA (3) CA2332369A1 (en)
CY (1) CY1105834T1 (en)
DE (6) DE29923847U1 (en)
DK (2) DK1079806T3 (en)
ES (2) ES2260915T3 (en)
HK (2) HK1035335A1 (en)
HU (3) HUP0102892A3 (en)
IL (4) IL139231A0 (en)
PT (2) PT1079806E (en)
RU (3) RU2212884C2 (en)
WO (3) WO1999060998A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2264827C2 (en) 1999-05-27 2005-11-27 Еуро-Селтик С.А. Preparations for removing antiphlogistic agents
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
CA2371689C (en) * 1999-05-27 2012-06-26 Wolfgang Fleischer Preparations for the application of anti-infective and/or anti-inflammatory agents to external or internal parts of the human or animal body in functional and cosmetic tissue remodelling and repair treatment
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6989157B2 (en) * 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
CA2432319A1 (en) 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE10125731A1 (en) * 2001-05-17 2003-03-06 A I D Autoimmun Diagnostika Gm Dosage form of immunological agents
DE10141650C1 (en) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
KR20040093155A (en) * 2002-03-18 2004-11-04 야마노우치세이야쿠 가부시키가이샤 Powdery medicinal compositions for inhalation and process for producing the same
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
KR101056410B1 (en) * 2002-11-11 2011-08-11 테이카 세이야쿠 가부시키가이샤 Damaged Skin Recovery Composition
WO2004066975A1 (en) 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
EP1449520A1 (en) * 2003-02-24 2004-08-25 Euro-Celtique S.A. Use of PVP-Iodine liposomes for treatment of herpes
ES2292874T3 (en) * 2003-05-19 2008-03-16 Euro-Celtique S.A. DRY LIPOSOMAL COMPOSITIONS OF PVP-IODINE.
US8651113B2 (en) 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US9028852B2 (en) 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
FR2878746B1 (en) 2004-12-02 2007-02-23 Vetoquinol Sa Sa NOVEL PHARMACEUTICAL COMPOSITION FOR USE IN THE FIELD OF VACCINES
WO2006099358A2 (en) 2005-03-10 2006-09-21 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxycarboxylic acids
EP3025704B1 (en) 2005-03-10 2019-01-16 3M Innovative Properties Company Methods of reducing microbial contamination
PL1962805T3 (en) 2005-12-08 2017-01-31 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
DE102006011314A1 (en) 2006-03-11 2007-10-18 Peter Dr. Engels Cosmetic preparations containing an additive from the baobab plant
RU2008142388A (en) * 2006-04-03 2010-05-10 Тева Фармасьютикл Индастриес Лтд. (Il) MEDICINAL PARTICLES OF THE MEDICINE
RU2315593C1 (en) * 2006-08-02 2008-01-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Antioxidant liposomal composition fir inhalation in lung and upper respiratory tract diseases
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
BRPI0716325A2 (en) 2006-10-27 2014-03-04 3M Innovative Properties Co ANTIMICROBIAN COMPOSITION
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
DK2222314T3 (en) * 2007-11-23 2013-04-15 Pharmalundensis Ab Uses and means for obtaining bronchial relaxation
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
KR20100048751A (en) * 2008-10-31 2010-05-11 주식회사 동성바이오레인 Capsulated functional dual core aerosol composition and the method for their manufacture
NL2002442C2 (en) 2009-01-22 2010-07-26 Weezenbeek Specialties B V Van Process for rejuvenating a composition containing a compound.
EP2226073A1 (en) 2009-03-02 2010-09-08 Euro-Celtique S.A. Topical pharmaceutical composition comprising an antiseptic and arginine for wound healing
US20110086084A1 (en) * 2009-10-13 2011-04-14 David William Koenig Active Agent Containing Polymer Network Delivery Composition and Articles Using the Same
JP6041811B2 (en) 2010-12-30 2016-12-14 “サイエンティフィク センター オブ アンティ−インフェクシャス ドラッグス”ジョイント−ストック カンパニー Antibacterial agents for treating bacterial infections
US9925251B2 (en) 2011-10-19 2018-03-27 President And Fellows Of Harvard College Treatments for Mycobacterium tuberculosis
KR101860485B1 (en) * 2011-11-03 2018-07-02 (주)아모레퍼시픽 Tissue for skin with nano-emulsion, method for manufacturing the same and method for using the same
CN108743537B (en) * 2012-05-21 2021-06-11 英斯麦德公司 System for treating pulmonary infections
RU2018135921A (en) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед STABILIZED VANCOMYCIN COMPOSITIONS
RU2538433C1 (en) * 2013-06-11 2015-01-10 Закрытое акционерное общество "ФИРН М" (ЗАО ФИРН М") Pharmaceutical composition for preventing and treating infectious-inflammatory diseases of various origins by oromucosal administration
EP3060198A4 (en) 2013-10-22 2017-06-28 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
RU2550932C1 (en) * 2014-03-18 2015-05-20 Александр Александрович Кролевец Method for producing cephalosporin nanocapsules in xanthum gum
US9968555B2 (en) * 2014-04-08 2018-05-15 Aradigm Corporation Liposomal formulations that form drug nanocrystals after freeze-thaw
WO2015157038A1 (en) 2014-04-08 2015-10-15 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
US20160120806A1 (en) * 2014-04-08 2016-05-05 Aradigm Corporation Nanocrystals formed in a microenvironment
ES2755941T3 (en) 2014-05-15 2020-04-24 Insmed Inc Methods of treating nontuberculous mycobacterial lung infections
EP3171881A4 (en) 2014-07-23 2018-01-10 Firebrick Pharma Pty Ltd Treatment and prevention of the common cold using povidone-iodine
KR102086150B1 (en) 2017-04-10 2020-03-06 부산대학교 산학협력단 in situ Hydrogel Forming Powder Composition for Wound Healing, and Method for Preparing thereof
FR3066115B1 (en) 2017-05-10 2019-06-28 Universite de Bordeaux COMPRESSES OF NUCLEIC ACID VECTORS
US20200289552A1 (en) * 2017-07-04 2020-09-17 Fluchem Ltd Solid composition comprising iodine agent and sodium chloride having improved water solubility, and antiviral and antimicrobial composition for eye, oral cavity, nasal cavity or inhalation containing aqueous solution thereof
WO2019009630A1 (en) * 2017-07-04 2019-01-10 김대황 Solid composition comprising iodine agent and sodium chloride having improved water solubility, and antiviral and antimicrobial composition for eye, oral cavity, nasal cavity or inhalation containing aqueous solution thereof
KR101935250B1 (en) * 2017-07-04 2019-01-04 김대황 Antiviral and antibacterial composition comprising iodide and osmotic tastant for eye, oral cavity, nasal cavity or inhalation
KR102026805B1 (en) 2017-12-12 2019-11-04 주식회사 크로파세 A anti-inflammation cosmetic composition
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019202400A1 (en) * 2018-04-17 2019-10-24 Universite De Caen Normandie Bambuterol for the treatment of alzheimer's disease
RU2730834C1 (en) * 2020-01-17 2020-08-26 Александр Александрович Кролевец Method of producing thymol nanocapsules
KR102244368B1 (en) * 2020-03-30 2021-04-27 현대바이오사이언스 주식회사 Ethosomal composition with tocopheryl acetate and dexpanthenol and method for preparing the same
CN111700883B (en) * 2020-07-23 2021-04-06 深圳大佛药业股份有限公司 Salbutamol sulfate sustained-release inhalation preparation and production process thereof
JP2022151438A (en) * 2021-03-26 2022-10-07 均 石井 Agents for treating conchitis and tympanitis
JP2022151426A (en) * 2021-03-26 2022-10-07 均 石井 Agents for treating upper respiratory inflammation

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE615889A (en) * 1952-04-15 1900-01-01
US4113857A (en) * 1977-05-16 1978-09-12 The Purdue Frederick Company Process for the preparation of iodophor compounds and methods for stabilizing iodophor pharmaceutical compositions containing the same
US4675009A (en) * 1977-11-07 1987-06-23 Lec Tec Corporation Drug dispensing device for transdermal delivery of medicaments
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
FR2536278A1 (en) * 1982-11-18 1984-05-25 Dupont Michele NOVEL THERAPEUTIC COMPOSITION USEFUL IN PARTICULAR FOR WOUND HEALING
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
FR2581542B1 (en) * 1985-05-07 1988-02-19 Oreal TOPICAL COMPOSITIONS FOR THE TREATMENT OF SKIN BASED ON SALICYLIC ACID DERIVATIVES
FR2591105B1 (en) * 1985-12-11 1989-03-24 Moet Hennessy Rech PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, OR COSMETIC, BASED ON HYDRATED LIPID LAMELLAR PHASES OR LIPOSOMES CONTAINING A RETINOIDE OR A STRUCTURAL ANALOG OF SUCH A RETINOID AS A CAROTENOID.
SE8603812D0 (en) * 1986-09-12 1986-09-12 Draco Ab ADMINISTRATION OF LIPOSOMES TO MAMMALS
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4938965A (en) * 1987-07-22 1990-07-03 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Ocular delivery of prophylactic agents
US5246708A (en) * 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
DE3826946C1 (en) * 1988-08-09 1990-03-15 A. Nattermann & Cie Gmbh, 5000 Koeln, De
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5232692A (en) * 1989-04-28 1993-08-03 Research And Education Institute, Inc. Povidone-iodine neonatal ophthalmic antimicrobial prophylactic agent
ATE111364T1 (en) * 1989-05-31 1994-09-15 Fisons Plc MEDICATION AND INHALER DEVICE THEREFOR.
US5089389A (en) * 1989-08-25 1992-02-18 Eastman Kodak Company Buffered composition, coated article test device and a method for their use
US5128139A (en) * 1991-02-15 1992-07-07 Nu Skin International, Inc. Composition containing liposome-entrapped grapefruit seed extract and method for making
DE4111982C2 (en) * 1991-04-12 1998-12-24 Merz & Co Gmbh & Co Stable small particulate liposome preparations, their preparation and use
KR0182801B1 (en) * 1991-04-16 1999-05-01 아만 히데아키 Method of manufacturing solid dispersion
AU666852B2 (en) * 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
WO1994014490A1 (en) * 1992-12-23 1994-07-07 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
US5552158A (en) * 1993-02-23 1996-09-03 Norac Technologies Inc. Skin care composition
DE4306475A1 (en) * 1993-03-02 1994-09-08 Ensenat Pedro Gonzalez Liposomes containing chlorhexidine diacetate or chlorhexidine digluconate
WO1994028876A1 (en) * 1993-06-07 1994-12-22 Advanced Therapies, Inc. Liposome powders
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5456904A (en) * 1993-06-28 1995-10-10 The Procter & Gamble Company Photoprotection compositions comprising certain chelating agents
US5863556A (en) * 1993-08-20 1999-01-26 Euro-Celtique, S.A. Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds
DE9312509U1 (en) * 1993-08-20 1993-10-28 Euro-Celtique S.A., Luxemburg/Luxembourg Preparations for external administration of antiseptic and / or wound healing promoting agents
NZ296098A (en) * 1994-11-04 2001-05-25 Polymun Scient Immunbio Forsch Super oxide dismutase in liposome and it's use in therapy
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
JPH08301774A (en) * 1995-05-08 1996-11-19 Kowa Co Throat disinfectant
US20010055610A1 (en) * 1997-06-06 2001-12-27 Shunji Nagata Medicament administration system
CA2371689C (en) * 1999-05-27 2012-06-26 Wolfgang Fleischer Preparations for the application of anti-infective and/or anti-inflammatory agents to external or internal parts of the human or animal body in functional and cosmetic tissue remodelling and repair treatment
US7300667B1 (en) * 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US7297344B1 (en) * 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
RU2264827C2 (en) * 1999-05-27 2005-11-27 Еуро-Селтик С.А. Preparations for removing antiphlogistic agents
US6497896B2 (en) * 2001-02-12 2002-12-24 Supergen, Inc. Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
ES2292874T3 (en) * 2003-05-19 2008-03-16 Euro-Celtique S.A. DRY LIPOSOMAL COMPOSITIONS OF PVP-IODINE.
WO2011008987A2 (en) * 2009-07-15 2011-01-20 Regents Of The University Of Minnesota Treatment and placement device for sinusitis applications

Similar Documents

Publication Publication Date Title
RU2000131695A (en) DRUG DELIVERY SYSTEM
AU747877B2 (en) Drug delivery system comprising a tightly compacted solid medicament stock
FI88108C (en) ORGANIC FREQUENCY PROCESSING, PHARMACEUTICAL, FAST COMPOSITION WITH PROLONGERED EFFECT
CA2115444C (en) Preparation for intratracheobronchial administration
EP1143931B1 (en) Pulmonary drug delivery
AU2015213678C1 (en) Mast cell stabilizers treatment for systemic disorders
CN1946380A (en) Oral disintegration preparation and its preparing method
WO2002024158A8 (en) Pulmonary delivery in treating disorders of the central nervous system
CN100400031C (en) Powdery preparations and proecss for producing the same
EP2213284A1 (en) Preparation for application to body surface and preparation holding sheet for application to body surface
AU2001275368A1 (en) Highly efficient delivery of a large therapeutic mass aerosol
WO2005025506A3 (en) Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
CN1915215A (en) Oral cavity disintegration preparation
WO1998055104A1 (en) Improvement in medicament administration system
JP2001518923A (en) Melatonin composition for nasal cavity
US20240123168A1 (en) Product delivery devices and methods
JP2006511617A (en) Pharmaceutical porous particles
CA2265198A1 (en) Method of producing a nicotine medicament and a medicament made by the method
CN204582192U (en) Sucking-assisting type pharmaceutical aerosol deposits day with fog
JP2004523536A (en) Drug
MXPA00011650A (en) Drug delivery system comprising a tightly compacted solid medicament stock
CN104523658B (en) Erdosteine powder inhalation and preparation method thereof
JP2962578B2 (en) Formulation in containers for intra-respiratory administration
CN101264068A (en) Ciclesonide dry powder inhalant and preparation thereof
JP2002255794A (en) Composition for pernasal administration capable of carrying out uniform multiple administration